Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors
出版年份 2022 全文链接
标题
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors
作者
关键词
-
出版物
Clinical Genitourinary Cancer
Volume 21, Issue 1, Pages 69-75
出版商
Elsevier BV
发表日期
2022-11-18
DOI
10.1016/j.clgc.2022.11.007
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.
- (2022) Simon J. Crabb et al. JOURNAL OF CLINICAL ONCOLOGY
- BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).
- (2022) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial.
- (2022) Francesca Vignani et al. JOURNAL OF CLINICAL ONCOLOGY
- RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
- (2021) Ramon Gonzalez Manzano et al. BMC CANCER
- TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
- (2021) Ivan de Kouchkovsky et al. Journal for ImmunoTherapy of Cancer
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
- (2021) Thomas Powles et al. NATURE MEDICINE
- A California Cancer Registry Analysis of Urothelial and Non-urothelial Bladder Cancer Subtypes: Epidemiology, Treatment, and Survival
- (2020) Jeremy W. Martin et al. Clinical Genitourinary Cancer
- Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
- (2020) G. L. Banna et al. Clinical & Translational Oncology
- Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
- (2020) Nazli Dizman et al. Journal for ImmunoTherapy of Cancer
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- (2020) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA
- (2020) Emily N. Risdon et al. ONCOLOGIST
- TERT—Regulation and Roles in Cancer Formation
- (2020) Marta Dratwa et al. Frontiers in Immunology
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer
- (2019) Jenny Roggisch et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
- (2019) Amin H. Nassar et al. BRITISH JOURNAL OF CANCER
- New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.
- (2018) Gregory Russell Pond et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- ATM/RB1 mutations predict shorter overall survival in urothelial cancer
- (2018) Ming Yin et al. Oncotarget
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
- (2016) Jakub Dobruch et al. EUROPEAN UROLOGY
- Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response
- (2016) M L Nickerson et al. ONCOGENE
- Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma
- (2016) Monika Joshi et al. Oncotarget
- Telomeres, lifestyle, cancer, and aging
- (2010) Masood A Shammas CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- The effect of age and gender on bladder cancer: a critical review of the literature
- (2009) Shahrokh F. Shariat et al. BJU INTERNATIONAL
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More